Expansion Momentum Vibalogics has recently expanded its manufacturing footprint with the addition of new facilities in Boston and Boxborough Massachusetts, totaling over 200,000 square feet. This significant capacity increase presents opportunities to offer customized CDMO services to clients aiming to scale up their biopharmaceutical production.

Investment in Infrastructure A $150 million investment into state-of-the-art manufacturing assets highlights Vibalogics' commitment to technological advancement and quality assurance. This focus on premium infrastructure positions the company as a reliable partner for innovative biotechs seeking high-quality manufacturing solutions.

Strategic Acquisition The acquisition by Recipharm enhances Vibalogics's financial stability and broadens its service portfolio, making it an appealing partner for companies looking for comprehensive biologics manufacturing capabilities integrated into a global network.

Growing Workforce Vibalogics plans to create over 100 new jobs in the Boston area, indicating ongoing operational expansion. This growth signals increased capacity and a readiness to handle larger or more complex client projects, ideal for companies seeking reliable manufacturing partnerships.

Focus on Innovative Therapies With extensive experience in viral vectors, gene therapies, and vaccines, Vibalogics is well-positioned to serve emerging biotech firms developing cutting-edge biotherapeutics, presenting sales opportunities in advanced clinical-stage partnerships and technological collaborations.